行情

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

实时行情|Nasdaq Last Sale

1.930
-0.040
-2.03%
已收盘, 16:00 10/17 EDT
开盘
1.960
昨收
1.970
最高
1.990
最低
1.910
成交量
7.48万
成交额
--
52周最高
27.60
52周最低
1.850
市值
4,646.94万
市盈率(TTM)
-0.2756
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EARS 新闻

  • 欧洲稳定机制负责人:我们不会像10年前那样陷入危机
  • 新浪美股.33分钟前
  • 达利欧:世界正处于大衰退阶段 各国央行已经无力回天
  • 新浪美股.44分钟前
  • 高盛CEO表示目前该行对WeWork的投资仍然盈利
  • 新浪美股.58分钟前
  • WeWork“大厦将倾” 软银、小摩“独木难支”
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
+0.83%
制药与医学研究
+0.62%

热门股票

名称
价格
涨跌幅

EARS 简况

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
展开

Webull提供Auris Medical Holding Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。